Toni Choueiri: Dr. Arlene Siefker-Radtkr presents the results of THOR

Quoting Toni Choueiri, the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute, on X/Twitter:

“To kick-off an exciting GU proffered session: Dr. Arlene Siefker-Radtkr presents the results of THOR:

– No OS benefit for erdafitinib vs pembro,
– Increased response rate with erdafitinib,
– While fewer responses to pembro, response is more durable.”

Source: Toni Choueiri/Twitter